DPP4 in Diabetes

DPP4 in Diabetes

Dipeptidyl peptidase 4 (DPP4) is a glycoprotein of 110 kDa, which is ubiquitously expressed on the surface of a variety of cells. This exopeptidase selectively cleaves N-terminal dipeptides from a variety of substrates, including cytokines, growth factors neuropeptides, and the incretin hormones. Ex...

Full description

Bibliographic Details
Main Authors:	Diana eRöhrborn, Nina eWronkowitz, Juergen eEckel
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2015-07-01
Series:	Frontiers in Immunology
Subjects:	Incretins multifunctional enzyme type 2 diabetes mellitus CD26/DPP4 soluble DPP4 DPP4 inhibitors/Gliptins
Online Access:	http://journal.frontiersin.org/Journal/10.3389/fimmu.2015.00386/full

Similar Items

Repurposing DPP-4 Inhibitors for Colorectal Cancer: A Retrospective and Single Center Study
by: Lui Ng, et al.
Published: (2021-07-01)

The regulatory role of DPP4 in atherosclerotic disease
by: Lihua Duan, et al.
Published: (2017-06-01)

National Council of Experts: the place of DPP-4 inhibitors in the treatment of patients with type 2 diabetes mellitus
by: M. V. Shestakova, et al.
Published: (2023-12-01)

DPP-4 inhibitors for treating T2DM - hype or hope? an analysis based on the current literature
by: Kunika Saini, et al.
Published: (2023-05-01)

CARDIOVASCULAR SAFETY OF GLIPTINS. FOCUS ON ALOGLIPTIN
by: N. A. Petunina, et al.
Published: (2017-12-01)

Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
by: Sharma A, et al.
Published: (2022-06-01)

Sitagliptin: the world’s first DPP-4 inhibitor
by: N. A. Petunina, et al.
Published: (2019-08-01)

Clinical Use of DPP-4 Inhibitors
by: Baptist Gallwitz
Published: (2019-06-01)

Establishment of a selective evaluation method for DPP4 inhibitors based on recombinant human DPP8 and DPP9 proteins
by: Jinglong Liu, et al.
Published: (2014-04-01)

Editorial – COVID-19 pandemic: is it time to learn about DPP-4/CD26?
by: M. Maia Pinheiro, et al.
Published: (2020-04-01)

Clinical implementetion of vildagliptin: data from recent studies comparing incretin-based medications
by: Elena Valer'evna Biryukova
Published: (2014-03-01)

Renoprotective Effects of DPP-4 Inhibitors
by: Daiji Kawanami, et al.
Published: (2021-02-01)

DPP4 Regulates the Th17/IL-17 Axis and Accelerates Epithelial Mesenchymal Transition to Promote Ovalbumin-Induced Asthma in Female C57BL/6J Mice
by: Linqiao Li, et al.
Published: (2023-12-01)

The effect of DPP-4 inhibition to improve functional outcome after stroke is mediated by the SDF-1α/CXCR4 pathway
by: Fausto Chiazza, et al.
Published: (2018-05-01)

Heart failure hospitalization with DPP-4 inhibitors: A systematic review and meta-analysis of randomized controlled trials
by: Awadhesh Kumar Singh, et al.
Published: (2019-01-01)

Clinical, Laboratory and Histological Features of Dipeptidyl Peptidase-4 Inhibitor Related Noninflammatory Bullous Pemphigoid
by: Ágnes Kinyó, et al.
Published: (2021-04-01)

Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
by: Editorial team Diabetes Mellitus
Published: (2012-06-01)

New prospects in the treatment of diabetes mellitus
by: Minara Shamkhalovna Shamkhalova, et al.
Published: (2012-12-01)

Hyperglycaemia induced osteoporosis: Is there a hope with dipeptidyl peptidase-4 inhibitors?
by: Faraha Ahmed, et al.
Published: (2023-12-01)

Distinctive CD26 Expression on CD4 T-Cell Subsets
by: Oscar J. Cordero, et al.
Published: (2021-10-01)

Efficacious and safe management of type 2 diabetes mellitus using DPP-4 inhibitors
by: Alexander Sergeevich Ametov, et al.
Published: (2010-06-01)

Dipeptidyl-Peptidase 4 Inhibitor-Induced Variants of Bullous Pemphigoid: A Case Series of Four Patients
by: Kamran Balighi, et al.
Published: (2022-11-01)

DPP-4 Inhibitors as Potential Candidates for Antihypertensive Therapy: Improving Vascular Inflammation and Assisting the Action of Traditional Antihypertensive Drugs
by: Jianqiang Zhang, et al.
Published: (2019-05-01)

Relevance of Autophagy Induction by Gastrointestinal Hormones: Focus on the Incretin-Based Drug Target and Glucagon
by: Keizo Kanasaki, et al.
Published: (2019-05-01)

Linagliptin: a thorough characterization beyond its clinical efficacy
by: Maria Angela eSortino, et al.
Published: (2013-02-01)

The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
by: Tianli Zhang, et al.
Published: (2021-12-01)

Experience with sitagliptin (the first DPP-4 inhibitor) application to the treatment of type 2 diabetes mellitus in the Russian Federation:Results of the DIA-DA observation program
by: Marina Vladimirovna Shestakova
Published: (2010-09-01)

Vildagliptin and its role in the treatment of diabetes mellitus
by: Yury Shavkatovich Khalimov
Published: (2010-09-01)

The Serine Protease CD26/DPP4 in Non-Transformed and Malignant T Cells
by: Guranda Chitadze, et al.
Published: (2021-11-01)

The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes
by: Eun Yeong Choe, et al.
Published: (2014-06-01)

The impact of DPP-4 inhibitors on long-term survival among diabetic patients after first acute myocardial infarction
by: Mei-Tzu Wang, et al.
Published: (2017-07-01)

DPP9: Comprehensive In Silico Analyses of Loss of Function Gene Variants and Associated Gene Expression Signatures in Human Hepatocellular Carcinoma
by: Jiali Carrie Huang, et al.
Published: (2021-04-01)

Linagliptin use in older individuals with type 2 diabetes
by: Pratley RE
Published: (2014-07-01)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
by: Matthew P. Gilbert, et al.
Published: (2020-04-01)

Dipeptidyl Peptidase Inhibition Enhances CD8 T Cell Recruitment and Activates Intrahepatic Inflammasome in a Murine Model of Hepatocellular Carcinoma
by: James M. Henderson, et al.
Published: (2021-11-01)

Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study)
by: Ghosh S, et al.
Published: (2016-11-01)

DPP4 as a Potential Candidate in Cardiovascular Disease
by: Chen SY, et al.
Published: (2022-09-01)

Alogliptin – the new member of DPP-4 inhibitors class
by: Nina Aleksandrovna Petunina, et al.
Published: (2014-12-01)

Incretins-Based Therapies and Their Cardiovascular Effects: New Game-Changers for the Management of Patients with Diabetes and Cardiovascular Disease
by: Federico Bernardini, et al.
Published: (2023-07-01)

Insight into Structure Activity Relationship of DPP-4 Inhibitors for Development of Antidiabetic Agents
by: Vishal Mathur, et al.
Published: (2023-08-01)